PT /SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB entrol number.

Complete if Known Substitute for form 1449A/PTO **Application Number** INFORMATION DISCLOSURE 10-29-2001 Filing Date Yingjian Wang STATEMENT BY APPLICANT First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code ² (<i>if known</i>	Publication Date MM-CD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
Tall		us- 5,143,854	09-01-199	2 Pirrung, et al.	
		us Described m	ethod.of.makir	g.ordered.arrays.of.nucle	ic acid sequences.
Œ.		us- us- 5,283,173		4—Fields-and-Song-	
		us- Descri	bed an in vivo	genetic method (yeast	two-hybrid screening)
		us to study protei	n-protein inter	actions	
W		us- us- 5,807,522-	09-15-199	8—Brown, et al.	
				and apparatus for fo	
		us biological sam	ples and for d	stribution of biological i	eagents to researchers
		US-through DNA	array. The mo	thod_involves_dispensing	a known volume of a
		us-reagent-at-eac	h-selected-arra	v-position-by-tapping-a	capillary-dispenser-on-
		us the support un	der-condition	effective-to-draw-a-de	ined-volume-of-liquid-
		us onto the suppo	rt.		
		US-			
	l ""	บร-			

	FOREIGN PATENT DOCUMENTS							
Examine: Initials	Cits No.1	Foreign Patent Document County Code 3 - Number 4 - Kind Code 9 (# Innern)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶		
						_		
						_		
						<u> </u>		
						_		

Examiner Signature	(de	I Law	Date Considered	12/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usoto.gog/ or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO N T SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/088 (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a callection of information unless it contains a valid OMB control mumber.

Col	mplete if Known
Application Number	
Films Date	10-29-2001
First Named Inventor	Yingjian Wang
Group Art Unit	

STATEMENT BY APPLICANT (use as many sheets as necessary) of Sheet

INFORMATION DISCLOSURE

Substitute for form 1449B/PTO

Examiner

Examiner Name Attorney Docket Number

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Can No.1	budude name of the author (in CAPITAL LETTERS), tide of the article (when appropriate), tide of the flam (book, magazine, journal, sarial, symposium, catalog, etc.), data, page(s), volume-issue number(a), authisber, city and/or country where published.	T2
K	2	BIGGIN, M.D. (1999) Ultraviolet-cross-linking-assay-to-measure sequence-specific DNA binding in vivo. Methods Enzymol. 304, 496-515. Described the applications of Cross-linking, including in studying protein-protein interactions, protein-DNA interactions.	
A.		BULYK ML, GENTALEN-E, LOCKHART DJ, CHURCH GM (1999) Quantifying DNA-protein interactions by double-stranded DNA arrays. Nature Biotechnology, 17:573-577. Described methods of using arrays of nucleic acids to detect DNA-protein interactions.	
\mathscr{Q}		DERISI J, PENLAND L, BROWN PO, BITTNER ML, MELTZER PS, RAY-M, CHEN-Y, SU YA, TRENT JM (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics 14:457-460. Described methods of using arrays of nucleic acids for large scale hybridization assays, including monitoring of gene expression	
OG		FIELDS AND SONG, A novel genetic system to detect protein-protein interactions. 1989, Nature, 340:245-246. Describe a new method of Yeast two-hybrid screening for detecting protein-protein interactions.	

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. control number.

Charetan &	r form 14498/PT	m			Complete if Known			
	•				Application Number			
INFOR	MATIO	N DI	SC	LOSURE	Filing Date	10-29-2001		
CTATI	EMENT	BY A	۱D	PLICANT	First Named Inventor	Yingiian Wang		
SIAII	EMEN!	D1 /	W.		Group Art Unit			
	(use as many :	sheets	es n	ecessary)	Examiner Name			
Sheet	3	of	_	5	Attorney Docket Number			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cãa No.¹	brotude name of the eathor (in CAPITAL LETTERS), title of the article (when appropriate), title of the farm (book, magazine, journet, serial, sympostum, catalog, etc.), date, page(s), volume-issue number(s), outlisher, city and/or country where outlished.	T ²
Œ		FODOR SP, READ JL, PIRRUNG MC, STRYER L, LU AT, SOLAS D. (1991) Light-directed, spatially addressable parallel chemical synthesis. Science, 251: 767-773. Described an alternate method of creating ordered arrays of nucleic acid sequences. The method involves synthesizing different nucleic acid sequences at different discrete regions of a support, usually made of glass:	
A)		GE, H. (2000) UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. <i>Nucleic Acids Research</i> , Vol. 28:e3. Describe the protein arrays and some of the applications.	
Ø,		HACIAJG(1999). Resequencing and mutational analysis using oligonucleotide microarrays. <i>Nat Genet</i> . 21(1 Suppl):42-7. Described methods of using DNA arrays to get nucleotide sequence information, including mutation detection, polymorphism detection and DNA sequencing	
Œ		KONONEN J, BUBENDORF L, KALLIONIEMI A, BARLUND M, SCHRAML P, LEIGHTON S, TORHORST J, MIHATSCH MJ, SAUTER G, KALLIONIEMI OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. <i>Nature Medicine</i> , 4:844-7. Described methods of using of tissue arrays in tumor screening.	

Examiner Date 00 16. Considered Signature

^{*}EXAMINER: Initial if reference considered, whicher or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS T THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/088 (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unters it contains a valid OMB control number.

					Complete if Known		
	r form 1449B/PTO				Application Number		
INFOR	MATION [NS	CLO	SURE	Filing Date	10-29-2001	
	EMENT BY				First Named Inventor	Yingjian Wang	
PIAII	EMENIDI	A	FFL	CAIT	Group Art Unit		
Ì	(use as many shee	ds as	necess	arv)	Examiner Name		
Sheet	4	of	5		Attorney Docket Number		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cita No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, cerial, symposium, cerating, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where outhished.	T ²				
A	2	PHIZICKY AND FIELDS, Protein-protein interactions: methods for detection and analysis. Microbiological Reviews, p94-123, Mar. 1995 Reviewed several methods for detecting protein-protein interactions.					
Qe		PRUSS, GAVIN, MELNIK AND BAVYKIN. DNA-protein cross-linking applications for chromatin studies in vitro and n vivo. Methods Enzymol., 304, 516-533, 1999) Described the applications of Cross-linking, including in studying protein-protein interactions, protein-DNA interactions.					
Q	2	SACHS, SCHECHTER, EASTLAKE AND ANFINSEN. Inactivation of staphylococcal nuclease by the binding of antibodies to a distinct antigenic determinant. Biochemistry 1972; 11(23): 4268-73. Discussed the interactions between antibodies and antigens.					
Œ		SCHENA M, SHALON D, DAVIS RW, BROWN PO (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470: Described methods of using arrays of nucleic acids for the monitoring of gene expressions.					
œ		SMITH, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. 1985, Science 228:1315-1317. Described the method of Phage display for screening protein-protein interactions.					

Considered Signature *EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Examiner

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Criter information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS T THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTC/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute f	for form 144SB/PTO		· · · · · · · · · · · · · · · · · · ·	Complete if Known		
				Application Number		
INFO	I NOTTAMS	DIS	CLOSURE	Films Date	10-29-2001	
STAT	EMENT BY	/ AL	PRICANT		Yingiian Wang	
JIAI.	FINEILI DI	- ~1	, LIONIII	Group Art Unit		
	(use as many shee	ets es	necessary)	Examiner Name		
Sheet	_	of	5	Attorney Docket Number		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	8 B	bridude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the firm (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where outlished.	T ²
A A		SOUTHERN EM, MASKOS U, ELDER JK (1992) Analyzing and comparing nucleic acid sequences by hybridization to arrays of oligonucleotides: evaluation using experimental models. Genomics 13:1008-1017. Described a related method to create arrays of nucleic acids by parallel synthesis. WANG, Y., WU, T.R., CAI, S., WELTE, T., AND CHIN, Y.E. (2000) Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol. Cell Biol. 20(13), 4505-12. Describe the use of antibody arrays in screening protein-protein interactions: WONG, SHAN S. (1993) Chemistry of protein conjugation and cross-linking. Boca Raton: CRC Press. Describe a variety of cross-linkers and a variety of methods to cross-link proteins:	
Examiner Signature		One Date Considered 12/16/04	5

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will avery depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.